000880211 001__ 880211
000880211 005__ 20230210112615.0
000880211 0247_ $$2CORDIS$$aG:(EU-Grant)893196$$d893196
000880211 0247_ $$2CORDIS$$aG:(EU-Call)H2020-MSCA-IF-2019$$dH2020-MSCA-IF-2019
000880211 0247_ $$2originalID$$acorda__h2020::893196
000880211 035__ $$aG:(EU-Grant)893196
000880211 150__ $$aTransforming Growth Factor – Bench To Bedside. Towards a better understanding of TGF-β isoform specific signalling in health and disease$$y2020-06-01 - 2023-07-31
000880211 371__ $$aUniversity of Leeds$$bUniversity of Leeds$$dUnited Kingdom$$ehttp://www.leeds.ac.uk/$$vCORDIS
000880211 372__ $$aH2020-MSCA-IF-2019$$s2020-06-01$$t2023-07-31
000880211 450__ $$aTGF-BTB$$wd$$y2020-06-01 - 2023-07-31
000880211 5101_ $$0I:(DE-588b)5098525-5$$2CORDIS$$aEuropean Union
000880211 680__ $$aTGF-BTB (Transforming Growth Factor – Bench To Bedside) is an ambitious and innovative project, the goal of which is to not only to understand the different roles of the TGF-β isoforms as well as in cell signalling at a molecular level, but also to explore their critical roles implicated in pathogenesis of fibrotic disorders and cancer. The dysregulation or complete shutdown of TGF-β pathway is responsible for many human diseases including connective tissue disorders, fibrotic disorders and the initiation and progression of soft tissue cancers. Most recent data show the importance of TGF-β in controlling the tumor microenvironment and its significance in the course of anticancer immunotherapies. The project will employ methods of structural and cell biology, together with in silico simulations, and will include the development of new tools, such as isoform-specific peptide-based inhibitors, engineered cytokines to study and manipulate the TGF-β canonical and non-canonical pathways. TGF-BTB is not only of great importance for increasing basic mechanistic understanding of TGF-β signalling, but also in terms of discovering potential new therapeutic avenues for treating diseases driven by excessive TGF-b signaling. During the outgoing phase, The Fellow, Dr Łukasz Wieteska, will join Prof Andrew Hinck’s research group at the University of Pittsburgh, which is a world class research laboratory at the forefront of TGF-β family structural studies. the Fellow will return to the University of Leeds to  continue his work with Prof John Ladbury, whose research has a strong focus on exploring the structural, biophysical, and cellular outcomes of the interplay of protein receptors in cell signalling pathways. Upon return, the Fellow will also benefit from a secondment at The Francis Crick Institute in the laboratory of Dr Caroline Hill, a leading researcher in the field of developmental biology with a special focus on TGF-β signaling.
000880211 909CO $$ooai:juser.fz-juelich.de:880211$$pauthority$$pauthority:GRANT
000880211 970__ $$aoai:dnet:corda__h2020::0b6cd1675c9ce0739c8c2cd4557b18e1
000880211 980__ $$aG
000880211 980__ $$aCORDIS
000880211 980__ $$aAUTHORITY